Abstract:Pemetrexed combined with platinum is a first-line therapy used to treat patients with advanced non-small cell lung cancer (NSCLC) that exhibit negative or unknown epidermal growth factor receptor (EGFR) mutational status or anaplastic lymphoma kinase (ALK) rearrangements. Lung adenocarcinoma (LAC) is the primary type of NSCLC. In order to prevent overtreatment, it is necessary to identify patients with LAC who may not benefit from certain chemotherapies. Patients recruited in the present study (n=129) were diagnosed with advanced LAC and received first-line pemetrexed and platinum-based chemotherapy. A microRNA (miR) microarray was used to screen the plasma miR expression profiles in a screening set of eight patients prior to and following treatment. Specifically, plasma miR-25, miR-21, miR-27b, miR-326, miR-483-5p and miR-920 were selected for reverse transcription-quantitative polymerase chain reaction analysis in a training set (n=44) prior to treatment. The screening and training set patients were all non-smokers with no prior history of serious or chronic disease. The ∆∆Cq values of these miRs were compared between the group that showed benefit from pemetrexed and platinum treatment and the group that did not. Consequently, the ∆∆Cq values of miR-25, miR-21, miR-27b and miR-326 were further determined in a validation set (n=77). The results of the present study demonstrate that plasma expression levels of miR-25, miR-21, miR-27b and miR-326, in the training and validation sets prior to treatment, were significantly different between the benefit and non-benefit groups (P≤0.001). The expression of miR-25, miR-21, miR-27b and miR-326 was upregulated in the non-benefit group and this elevation was positively correlated with decreased progression-free survival (PFS; P≤0.001). In addition, the predictive power of each miR was evaluated through receiver operating characteristic curves, in which miR-25 exhibited the highest degree of accuracy (area under the curve, 0.926; 95% confidence interval, 0.881-0.971). These results indicate that overexpression of plasma miR-25, miR-21, miR-27b and miR-326, prior to treatment, in patients with advanced LAC is predictive of non-benefit from first-line pemetrexed and platinum-based chemotherapy, and is associated with decreased PFS. Among these four miRs, miR-25 exhibited the highest degree of accuracy in predicting insensitivity, suggesting it is the most promising biomarker.

MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer.

Identification of Plasma miRNA-21 as a Biomarker for Diagnosis and Chemotherapy Prognosis in Non-Small Cell Lung Cancer

MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment

Identification of Plasma Microrna-21 As a Biomarker for Early Detection and Chemosensitivity of Non-Small Cell Lung Cancer

Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-Small Cell Lung Cancer

Evaluation of Plasma Microrna Levels to Predict Insensitivity of Patients with Advanced Lung Adenocarcinomas to Pemetrexed and Platinum

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer.

Increased Expression of Microrna-21And Its Association with Chemotherapeutic Response in Human Colorectal Cancer.

Prognostic Role of Circulating Exosomal Mir-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.

Deregulated Expression of Mir-21, Mir-143 and Mir-181A in Non Small Cell Lung Cancer is Related to Clinicopathologic Characteristics or Patient Prognosis

microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation

Down-Regulating the Expression of miRNA-21 Inhibits the Glucose Metabolism of A549/DDP Cells and Promotes Cell Death Through the PI3K/AKT/mTOR/HIF-1α Pathway

MicroRNA-21 As a Diagnostic and Prognostic Biomarker of Lung Cancer: a Systematic Review and Meta-Analysis.

MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer

Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer

miR-21 and miR-145 as Prognostic Biomarkers for Radiotherapy Responses in Cervical Cancer Patients: A Preliminary Study

Analysis of Micrornas in Drug-Resistant NSCLC Cell Line A549/DDP

High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer